论文部分内容阅读
目的探讨朝藿定B在大鼠体内的代谢产物及转化途径。方法选择SD大鼠12只,分为2组,肌肉注射组和口服给药组,收集给药前和给药后0~24 h尿样和粪便样品,采用高效液相色谱-串联线性离子阱静电场轨道阱质谱仪(LC-LTQ Orbitrap MSn)检测。结果通过比较给药前后各组总离子流色谱图,对尿和粪便中推测的代谢物和标准物质的出峰时间及相关化合物的多级串联质谱数据进行了分析,结果在粪便中发现了14种药物代谢产物,系统分析了这些代谢产物的代谢转化规律及可能的结构。而尿液中代谢产物的数量和含量远低于粪便,最终在尿液中找到的4种微量代谢产物,其在粪便中均有发现。结论朝藿定B在大鼠体内的主要转化途径为结合、水解、氧化、加成及脱甲基反应等。
OBJECTIVE To investigate the metabolic products and the conversion of Epimedin B in rats. Methods Twelve SD rats were selected and divided into two groups: intramuscular injection group and oral administration group. Urine samples and stool samples were collected before drug administration and 0-24 hours after drug administration. High-performance liquid chromatography-tandem linear ion trap Electrostatic field orbitrap mass spectrometry (LC-LTQ Orbitrap MSn) detection. Results By comparing the total ion chromatogram of each group before and after administration, the peak time of metabolites and reference substances in urine and feces and the multistage tandem mass spectrometry data of related compounds were analyzed. As a result, 14 Drug metabolites, systematic analysis of the metabolic transformation of these metabolites and possible structure. The amount and content of metabolites in urine is much lower than the feces, and finally found in the urine of four kinds of trace metabolites, which are found in the feces. Conclusion The main conversion pathway of Epimedin B in rats is binding, hydrolysis, oxidation, addition and demethylation.